Synonyms CBF-AML - core binding factor acute myeloid leukemia, Core Binding Factor Acute Myeloid Leukemia, Core binding factor acute myeloid leukaemia + [4] |
Introduction Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis. |
Mechanism FLT3 inhibitors [+5] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date28 Apr 2017 |
Target |
Mechanism Bcl-2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date11 Apr 2016 |
Target |
Mechanism POLA1 inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date28 Dec 2004 |
Start Date20 Nov 2025 |
Sponsor / Collaborator |
Start Date16 Dec 2024 |
Sponsor / Collaborator- |
Start Date21 Sep 2024 |
Sponsor / Collaborator |